News | October 28, 2021
Indian Pharma Market witnesses rise in volumes and prices in September.
Acute therapies continue to report strong growth compared to chronic ones.
Acute therapies continue to report strong growth compared to chronic ones.
Post normalisation of high growth months of April and May this year the average IPM growth from June to August this year stood at 15.2 % YoY : Ind-Ra reports
The company said Revital NXT is India’s first nutrition bar with the goodness of natural ginseng, 16 vitamins & minerals and triple blend protein
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The focus is on wellness and personal care products
At present 18 per cent of the local pharmaceutical market is under government's price control
The segment delivered strong sales growth of 20% YoY
Domestic business was up 41.9% YoY and 27.7% QoQ
Demand normalisation post the second wave contributed to the steady growth
Adjusted PAT declined 18.8% YoY
Subscribe To Our Newsletter & Stay Updated
